ALC vs SLS
Alcon Inc vs SELLAS Life Sciences Group, Inc. — AI-powered side-by-side comparison
VS
SLS
SELLAS Life Sciences Group, Inc.
57
Watch
| Metric | ALC | SLS |
|---|
| AI Score |
68
|
57
|
| Price |
$75.39
|
$11.03
|
| P/E Ratio |
45.39×
|
-52.30×
|
| ROE |
4.4%
|
-37.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
0.0%
|
| Debt / Equity |
0.24×
|
0.01×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
43.9
|
| Beta |
0.703
|
2.494
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus SLS.
ALC leads by 11 points.
ALC scores 68/100 (Buy) versus SLS at 57/100 (Watch).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
SLS Committee View
80% agreement
5 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 7.6x prices in significant intangible value — Value
- ROE of only -47.1% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical